NCT07684274Not yet recruiting
Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics
Source: ClinicalTrials.gov · Last updated 6 Jul 2026
Brief summary (registry, in English)
Study on Early Screening of Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Technology. This study aims to construct and validate a set of machine learning models for the early screening of myeloma tailored to the Chinese population, based on plasma cfDNA fragmentomics features, to effectively distinguish myeloma patients from healthy individuals.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 290 (estimated)
- First submitted
- 12 Jun 2026
- Start date
- 13 Jun 2026
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- The First Affiliated Hospital with Nanjing Medical University
- Diseases
- Multiple myeloma
- NCT number
- NCT07684274
What you commit to
- Study type: Observational
- Planned participants: 290
- From 13 Jun 2026 to the primary completion date, 31 Jul 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- History of blood transfusion within 7 days prior to blood collection.
Other illness
- Prior cancer diagnosis within the past 5 years, or history of any form of systemic cancer therapy (including chemotherapy, targeted therapy, immunotherapy, etc.).
- History of organ transplantation, or allogeneic bone marrow or stem cell transplantation.
- Poor compliance or potential interference with signing informed consent as judged by the investigator, or any other conditions rendering the subject unsuitable for the study.
Other
- Pregnant or lactating women.
Who the study is looking for
- Age over 40 years.
- Diagnosed with MM, SMM, or MGUS through standard diagnostic procedures.
- Voluntarily participating and signed written informed consent.
Age in the registry: 40 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.